草船借箭 发表于 2014-7-15 10:04& i, ~% G1 J4 p5 K: Y* l' t9 Z
http://www.18222788817.com/kangairiji/2013/24.html- @+ L- Y8 X! H8 b
易瑞沙如何减量服用？
The efficacy of low-dose gefitinib for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations: A post-hoc analysis from NEJ002.7 `! s+ R# @9 @7 r
* S( @; X |6 h, I& E4 ^4 u2 fAbstract:
. b# j( l# B1 p+ n1 J
; p( X/ Q a& v; gBackground: NEJ002, a phase III trial comparing gefitinib with carboplatin-paclitaxel as the first-line treatment for advanced NSCLC with sensitive EGFR mutations, showed a significant improvement in progression-free survival (PFS) in the gefitinib arm. Although standard schedule of gefitinib was the administration of 250 mg tablet every day, more than half of patients in the gefitinib arm reduced the dose of gefitinib mainly because of toxicities. However, the efficacy of such low-dose (LD) gefitinib has rarely been evaluated.
& z0 h- d+ |7 I9 X R8 E) @0 e6 l/ t2 ^
Methods: A post-hoc analysis of the efficacy (response rate and survival) in patients who took gefitinib without any dose reduction during their treatment period and those in patients who received LD gefitinib at any point during the treatment period was performed.
. n) {. R& t: ^4 _6 u2 W" ^ T. F; f! h- E
Results: Among 114 patients of the first-line gefitinib group in NEJ002, 52 (46%) continued gefitinib without break until their diseases progressed (categorize as group A), and 62 (54%) was reduced their dose of gefitinib (most of them moved into every-2-days schedule) because of some toxicities (same as group B). There was no significant difference of patient characteristics between two groups. Interestingly, PFS of group B seemed to be better than that of group A (median PFS, 301 days in group A versus 351 days in group B; p = 0.450) and overall survival was also similar between the groups (median survival time, 852 days versus 928 days, respectively; p = 0.674).
- F4 r7 s! y: @; I62名患者减量服用吉非替尼(大多数换成了两天一片的用药方案)/ ~- k Y# {% D& Z
4 c, d! |* _" yConclusions: The results suggest that LD gefitinib may be clinically not inferior to standard schedule of gefitinib for NSCLC with sensitive EGFR mutations. Considering the merit in terms of risk-benefit balance, prospective study of LD gefitinib is warranted.
o& I8 v% _) N9 E9 c1 H0 g @( [- e3 m0 R* e5 ?
http://meetinglibrary.asco.org/content/43760-74 |
镇痛有道—关于癌痛二三事--讲座记录
镇痛有道—关于癌痛二三事主讲人：何志勇 1. 癌痛定义（范围）：由肿瘤本身直接引起
长期服用阿来耐药后，洛拉、放疗快速
一、患者主要治疗经过
患者2015年肺癌手术后，2019年底脑多发转移（原发无病灶），20
总生存期延长近5年！多种小细胞肺癌
作者：Tony
美国的ASCO，欧洲的ESMO，中国的CSCO。
2024年CSCO学术年会于9月26日在厦
【基因检测，人人可及】肿瘤患者免费
【基因检测，人人可及】肿瘤患者免费基因检测公益援助
与癌共舞论坛联手吉因加推出的
求助 K药和替雷利珠如何选择
父亲9月刚查出非小细胞低分化癌伴随左肾上腺和第10胸椎转移PDL1高表达(TPS=90%) SMARC
显身卡
